Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia
- 18 September 1990
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 66 (8) , B31-B38
- https://doi.org/10.1016/0002-9149(90)90438-7
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Causes of high blood cholesterol.Circulation, 1990
- Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.Circulation, 1989
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987
- In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia.Journal of Clinical Investigation, 1986
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1984
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981